M M van den Heuvel
Overview
Explore the profile of M M van den Heuvel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kicken M, Deenen M, van der Wekken A, van den Borne B, van den Heuvel M, Ter Heine R
Clin Pharmacokinet
. 2025 Mar;
PMID: 40045151
Precision dosing of classical cytotoxic drugs in oncology remains underdeveloped, especially in treating non-small cell lung cancer (NSCLC). Despite advancements in targeted therapy and immunotherapy, classical cytotoxic agents continue to...
2.
de Rouw N, Beunders R, Hartmann O, Schulte J, Boosman R, Derijks H, et al.
Cancer Chemother Pharmacol
. 2024 Oct;
94(6):799-806.
PMID: 39365467
Introduction: For drugs with a narrow therapeutic window, there is a delicate balance between efficacy and toxicity, thus it is pivotal to administer the right dose from the first administration...
3.
Schouten R, Schouten I, Schuurbiers M, van der Noort V, Damhuis R, van der Heijden E, et al.
PLoS One
. 2024 Jul;
19(7):e0290939.
PMID: 39083479
Introduction: Molecular profiling of NSCLC is essential for optimising treatment decisions, but often incomplete. We assessed the efficacy of protocolised molecular profiling in the current standard-of-care (SoC) in a prospective...
4.
Verheijen R, van Duijl T, van den Heuvel M, Vessies D, Muller M, Beijnen J, et al.
Cancer Chemother Pharmacol
. 2021 Jan;
87(2):269-276.
PMID: 33484280
Purpose: We studied EGFR mutations in circulating tumor DNA (ctDNA) and explored their role in predicting the progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients treated with erlotinib...
5.
Garde E, van Bedaf L, Hurkmans D, van den Heuvel M
Ann Oncol
. 2020 Sep;
31(12):1779-1780.
PMID: 32976935
No abstract available.
6.
Theelen W, Krijgsman O, Monkhorst K, Kuilman T, Peters D, Cornelissen S, et al.
J Transl Med
. 2020 Jul;
18(1):271.
PMID: 32620126
Background: The tumor immune microenvironment is a heterogeneous entity. Gene expression analysis allows us to perform comprehensive immunoprofiling and may assist in dissecting the different components of the immune infiltrate....
7.
de Rouw N, Boosman R, van de Bruinhorst H, Biesma B, van den Heuvel M, Burger D, et al.
Lung Cancer
. 2020 Jun;
146:30-35.
PMID: 32505078
Introduction: Pemetrexed is a pharmacotherapeutic cornerstone in the treatment of non-small cell lung cancer. As it is primarily eliminated by renal excretion, adequate renal function is essential to prevent toxic...
8.
Thunnissen E, Lissenberg-Witte B, van den Heuvel M, Monkhorst K, Skov B, Sorensen J, et al.
Lung Cancer
. 2019 Oct;
138:13-18.
PMID: 31630043
Objective: Metastasized non-small cell lung cancer (NSCLC) with an anaplastic lymphoma kinase (ALK) rearrangement is usually sensitive to a range of ALK-tyrosine kinase inhibitors. ALK-positive NSCLC have been identified in...
9.
de Vries R, Muller M, van der Noort V, Theelen W, Schouten R, Hummelink K, et al.
Ann Oncol
. 2019 Sep;
30(10):1660-1666.
PMID: 31529107
Background: Immune checkpoint inhibitors have improved survival outcome of advanced non-small-cell lung cancer (NSCLC). However, most patients do not benefit. Therefore, biomarkers are needed that accurately predict response. We hypothesized...
10.
de Haan R, van Werkhoven E, van den Heuvel M, Peulen H, Sonke G, Elkhuizen P, et al.
BMC Cancer
. 2019 Sep;
19(1):901.
PMID: 31500595
Background: Poly (ADP-ribose) Polymerase (PARP) inhibitors are promising novel radiosensitisers. Pre-clinical models have demonstrated potent and tumour-specific radiosensitisation by PARP inhibitors. Olaparib is a PARP inhibitor with a favourable safety...